Literature DB >> 25204652

Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions.

Hongfei Ge1, Jun Zhang1, Yan Gong1, Jamila Gupte1, Jay Ye1, Jennifer Weiszmann1, Kim Samayoa1, Suzanne Coberly1, Jonitha Gardner1, Huilan Wang2, Tim Corbin2, Danny Chui2, Helene Baribault1, Yang Li3.   

Abstract

The role of fibroblast growth factor receptor 4 (FGFR4) in regulating bile acid synthesis has been well defined; however, its reported role on glucose and energy metabolism remains unresolved. Here, we show that FGFR4 deficiency in mice leads to improvement in glucose metabolism, insulin sensitivity, and reduction in body weight under high fat conditions. Mechanism of action studies in FGFR4-deficient mice suggest that the effects are mediated in part by increased plasma levels of adiponectin and the endocrine FGF factors FGF21 and FGF15, the latter of which increase in response to an elevated bile acid pool. Direct actions of increased bile acids on bile acid receptors, and other potential indirect mechanisms, may also contribute to the observed metabolic changes. The results described herein suggest that FGFR4 antagonists alone, or in combination with other agents, could serve as a novel treatment for diabetes.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Bile Acid; Diabetes; FGF15; FGF19; FGF21; FGFR4; Glucose Metabolism; Insulin; Obesity

Mesh:

Substances:

Year:  2014        PMID: 25204652      PMCID: PMC4215229          DOI: 10.1074/jbc.M114.592022

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.

Authors:  A N Plotnikov; S R Hubbard; J Schlessinger; M Mohammadi
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

3.  Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Jennifer Weiszmann; Jamila Gupte; Nessa Hawkins; Xiaofan Li; Jie Tang; Richard Lindberg; Yang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

4.  Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.

Authors:  Misato Kobayashi; Hiroshi Ikegami; Tomomi Fujisawa; Koji Nojima; Yumiko Kawabata; Shinsuke Noso; Naru Babaya; Michiko Itoi-Babaya; Kaori Yamaji; Yoshihisa Hiromine; Masao Shibata; Toshio Ogihara
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 5.  Structural and functional diversity in the FGF receptor multigene family.

Authors:  D E Johnson; L T Williams
Journal:  Adv Cancer Res       Date:  1993       Impact factor: 6.242

Review 6.  Targeting bile-acid signalling for metabolic diseases.

Authors:  Charles Thomas; Roberto Pellicciari; Mark Pruzanski; Johan Auwerx; Kristina Schoonjans
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

7.  Dual actions of fibroblast growth factor 19 on lipid metabolism.

Authors:  Xinle Wu; Hongfei Ge; Hélène Baribault; Jamila Gupte; Jennifer Weiszmann; Bryan Lemon; Jonitha Gardner; Preston Fordstrom; Jie Tang; Mingyue Zhou; Minghan Wang; Yang Li
Journal:  J Lipid Res       Date:  2012-12-02       Impact factor: 5.922

8.  FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver.

Authors:  Xinqiang Huang; Chaofeng Yang; Yongde Luo; Chengliu Jin; Fen Wang; Wallace L McKeehan
Journal:  Diabetes       Date:  2007-07-30       Impact factor: 9.461

9.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Authors:  Ling Fu; Linu M John; Sean H Adams; Xing Xian Yu; Elizabeth Tomlinson; Mark Renz; P Mickey Williams; Robert Soriano; Racquel Corpuz; Barbara Moffat; Richard Vandlen; Laura Simmons; Jessica Foster; Jean-Philippe Stephan; Siao Ping Tsai; Timothy A Stewart
Journal:  Endocrinology       Date:  2004-02-19       Impact factor: 4.736

10.  FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.

Authors:  Ai-Luen Wu; Sally Coulter; Christopher Liddle; Anne Wong; Jeffrey Eastham-Anderson; Dorothy M French; Andrew S Peterson; Junichiro Sonoda
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

View more
  25 in total

Review 1.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

2.  β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.

Authors:  Emmanuel Somm; Hugues Henry; Stephen J Bruce; Sébastien Aeby; Marta Rosikiewicz; Gerasimos P Sykiotis; Mohammed Asrih; François R Jornayvaz; Pierre Damien Denechaud; Urs Albrecht; Moosa Mohammadi; Andrew Dwyer; James S Acierno; Kristina Schoonjans; Lluis Fajas; Gilbert Greub; Nelly Pitteloud
Journal:  JCI Insight       Date:  2017-04-20

3.  Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins.

Authors:  Samir Softic; Jesse G Meyer; Guo-Xiao Wang; Manoj K Gupta; Thiago M Batista; Hans P M M Lauritzen; Shiho Fujisaka; Dolors Serra; Laura Herrero; Jennifer Willoughby; Kevin Fitzgerald; Olga Ilkayeva; Christopher B Newgard; Bradford W Gibson; Birgit Schilling; David E Cohen; C Ronald Kahn
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

4.  In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator.

Authors:  Ingrid C Rulifson; Patrick Collins; Li Miao; Dana Nojima; Ki Jeong Lee; Miki Hardy; Jamila Gupte; Kelly Hensley; Kim Samayoa; Cynthia Cam; James B Rottman; Mike Ollmann; William G Richards; Yang Li
Journal:  J Biol Chem       Date:  2016-12-23       Impact factor: 5.157

Review 5.  Effect of ethanol on lipid metabolism.

Authors:  Min You; Gavin E Arteel
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

6.  Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos.

Authors:  Rupal Mehta; Xuan Cai; Alexander Hodakowski; Bharat Thyagarajan; Donglin Zeng; Phyllis C Zee; William K Wohlgemuth; Susan Redline; James P Lash; Myles Wolf; Tamara Isakova
Journal:  Bone       Date:  2018-07-03       Impact factor: 4.398

Review 7.  Endocrine Adiponectin-FGF15/19 Axis in Ethanol-Induced Inflammation and Alcoholic Liver Injury.

Authors:  Min You; Zhou Zhou; Michael Daniels; Alvin Jogasuria
Journal:  Gene Expr       Date:  2017-11-02

8.  MitoNEET Deficiency Alleviates Experimental Alcoholic Steatohepatitis in Mice by Stimulating Endocrine Adiponectin-Fgf15 Axis.

Authors:  Xudong Hu; Alvin Jogasuria; Jiayou Wang; Chunki Kim; Yoonhee Han; Hong Shen; Jiashin Wu; Min You
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

9.  Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.

Authors:  Qian Lin; Zhifeng Huang; Genxiang Cai; Xia Fan; Xiaoqing Yan; Zhengshuai Liu; Zehua Zhao; Jingya Li; Jia Li; Hongxue Shi; Maiying Kong; Ming-Hua Zheng; Daniel J Conklin; Paul N Epstein; Kupper A Wintergerst; Moosa Mohammadi; Lu Cai; Xiaokun Li; Yu Li; Yi Tan
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.425

10.  FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.

Authors:  Tianli Chen; Hongda Liu; Zengli Liu; Kangshuai Li; Ruixi Qin; Yue Wang; Jialiang Liu; Zhipeng Li; Qinglun Gao; Chang Pan; Fan Yang; Wei Zhao; Zongli Zhang; Yunfei Xu
Journal:  Oncogene       Date:  2021-06-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.